| Form | Liquid |
|---|---|
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Purification | Purified by antigen affinity column. |
| Endotoxin Level | Please contact with the lab for this information. |
| Applications | ELISA, IHC, WB |
| Species Reactivity | Human |
| Target | EC:1.7.-.-, MARC1, MOSC domain-containing protein 1, MOSC1, MTARC1, Mitochondrial amidoxime-reducing component 1, Moco sulfurase C-terminal domain-containing protein 1, Molybdenum cofactor sulfurase C |
| Immunogen | E. coli - derived recombinant Human MTARC1 (Arg41-Leu335). |
| Storage Buffer | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
| Product Usage Information | ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000 |
| Accession Number | Q5VT66 |
| Background | Mitochondrial amidoxime-reducing component 1 (MTARC1) is a ~37 kDa protein. Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transfer from NADH to cytochrome b5 reductase then to cytochrome b5, the ultimate electron donor that primes the active site for substrate reduction. 1. Gruenewald, S. et al. (2008) Journal of medicinal chemistry 51, 8173-7. PMID: 19053771 2. Kotthaus, J. et al. (2011) The Biochemical journal 433, 383-91. PMID: 21029045 3. Kubitza, C. et al. (2018) Proceedings of the National Academy of Sciences of the United States of America 115, 11958-11963. PMID: 30397129 |
| Note | For research use only |